Fabrazyme Articles
Genzyme Framingham plant now cleared by US and EU regulators
24 January 2012
Ongoing supply problems for Genzyme’s Cerezyme
19 September 2011
Shire says Fabry and Gaucher disease studies continue to support patient switches to Replagal and Vpriv
1 September 2011
Genzyme’s 2nd-qtr 2010 profits plunge on continuing Cerezyme and Fabrazyme supply problems
22 July 2010
US FDA to take enforcement action regarding Genzyme’s Allston plant, including financial penalties
25 March 2010
Icahn seeks to influence Genzyme, nominating four board directors
23 February 2010
Genzyme’s 4th quarter 2009 earnings plunge due to manufacturing problems for two leading products; expands research in Europe
18 February 2010
Pfizer to pay Protalix up to $115 million in Gaucher's disease treatment deal; Genzyme’s Cerezyme supply
2 December 2009
FDA finds trash particles in Genzyme’s drugs, leading firm to advise health care providers
16 November 2009
Third-quarter 2009 profit sinks at Genzyme, on production woes
22 October 2009
Genzyme updates on Cerezyme and Fabrazyme sales now supply back on line
24 September 2009
Genzyme's 2008 profit down on costs
23 February 2009
Genzyme's 3rd-qtr 2008 profit down 25%
3 November 2008
Genzyme's 2nd qtr profit hit by license cost
4 August 2008
Genzyme's 1st-qtr revenues jump 25%
5 May 2008
Genzyme's 4th-qtr 2007 revenue jumps 21%
25 February 2008
Strong third quarter for Genzyme: GAAP net income reaches $159M on the back of good sales
5 November 2007
Genzyme's 2nd-qtr net income jumps 4%
6 August 2007
Genzyme's 1st-qtr net income soars 57%
7 May 2007
Genzyme's 2nd-qtr 2006 revenue rises 19%
24 July 2006
Genzyme's 1st-qtr sales less than expected
1 May 2006
Amicus' Amigal gets OD nod from COMP
24 April 2006
Genzyme guidance upped on good 2nd qtr
25 July 2005
Genzyme's 1st-qtr revenues up 28%
25 April 2005
Genzyme $57.3M net loss for 4th qtr 2004
28 February 2005
Myzozyme MAA lifts Genzyme
10 January 2005
Genzyme swings to profit in 3rd qtr
1 November 2004
Clinical benefits of Fabrazyme confirmed
27 September 2004
Genzyme's 2nd-qtr revenues jump 58%
19 July 2004
Genzyme posts 1st-qtr net income of $67.9M
26 April 2004
Genzyme to buy ILEX for $1 billion
8 March 2004
TKT's Replagal cleared in Canada
16 February 2004
TKT will not seek US OK for Replagal
19 January 2004
Genzyme swings to loss on acquisition costs
27 October 2003
Genzyme receives rare boost in 2nd qtr
21 July 2003
SEC investigates TKT's Replagal disclosures
26 May 2003
FDA clears Genzyme, BioMarin drug for MPS
12 May 2003
Stock Commentary - New York
5 May 2003
Renagel sales boost Genzyme in 1st-qtr
28 April 2003
4th-qtr charges hit Genzyme General
17 March 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
FDA panel backs approval of Fabrazyme
20 January 2003
FDA panel backs Fabrazyme, but not Replagal for Fabry disease
20 January 2003
Stock Commentary week to Jan 13 - New York
20 January 2003
FDA panel dates set for Fabry disease rivals
15 July 2002
Update: Mixed fortunes for Fabry disease rivals
24 October 2001
FDA delays Fabrazyme decision
23 October 2001
Genzyme Fabry drug in France under an ATU
22 January 2001
Genzyme hit by delay to Fabrazyme; opportunity for TKT?
2 January 2001
Fabrazyme
3 November 2000
Genzyme files patent suit against TKT
27 July 2000
Transkaryotic files BLA for Replagel
20 June 2000
Genzyme to file BLA for Fabrazyme in 2Q 2000
4 May 2000
Showing 1-74 of 74 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
